Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half no longer meeting the BMI criteria for obesity Participants with a baseline BMI of 35 or higher who took retatrutide 12 mg lost up to...
Covered in this story
Call it yourself
No calls on $BMI yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Badger Meter Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.